Reducing Pancreatic Cancer Risk Through Chemoprevention
Dr. Peter Allen leads a clinical trial of chemoprevention–the use of a medication to prevent IPMNs from developing into pancreatic cancer.
Dr. Peter Allen leads a clinical trial of chemoprevention–the use of a medication to prevent IPMNs from developing into pancreatic cancer.
The research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Researchers are using blood samples to follow people considered at-risk for developing pancreatic cancer in a trial looking for early detection biomarkers.
Dr. Anne Marie Lennon explains CompCyst, the artificial intelligence-based assay that can determine the best treatment for pancreatic cysts.
Dr. V. Raman Muthusamy explains the difference between pancreatic cysts and pancreatic cancer, and tells you which types of cysts may have cancer potential.
Have you or someone you love just been diagnosed with pancreatic cancer? Learn some basic facts about this disease from our FAQ.
One focus of research for Dr. Anirban Maitra is to develop a simple screening test for pancreatic cancer, to provide an earlier diagnosis of the disease.